Merck has signed a collaboration agreement with the UK’s Avillion under which the latter will develop the German drug giant’s anti IL-17 A/F Nanobody as a treatment for plaque psoriasis.
Pfizer and partner Avillion have presented data from a late-stage study showing that Bosulif was better than Novartis’ Gleevec as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.